Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure.
نویسندگان
چکیده
The novel hormone ghrelin is a potent orexigen that may counterbalance leptin. Ghrelin is the only secreted molecule requiring post-translational acylation with octanoic acid to ensure bioactivity. Ghrelin, predominantly derived from the stomach, may target neuroendocrine networks within the central nervous system (CNS) to regulate energy homeostasis. This would require ghrelin to cross the blood-brain barrier (BBB). In mice, we examined whether ghrelin crosses the BBB and whether its lipophilic side chain is involved in this process. We found that saturable systems transported human ghrelin from brain-to-blood and from blood-to-brain. Mouse ghrelin, differing from human ghrelin by two amino acids, was a substrate for the brain-to-blood but not for the blood-to-brain transporter and so entered the brain to a far lesser degree. des-Octanoyl ghrelin entered the brain by nonsaturable transmembrane diffusion and was sequestered once within the CNS. In summary, we show that ghrelin transport across the BBB is a complex, highly regulated bidirectional process. The direction and extent of passage are determined by the primary structure of ghrelin, defining a new role for the unique post-translational octanoylation.
منابع مشابه
Interactions of Growth Hormone, Insulin-Like Growth Factor-1, and Ghrelin with the Blood-Brain Barrier
Growth hormone (GH) therapy is associated with improved neurobehavior, leading to the question whether GH crosses the blood-brain barrier (BBB) from blood after its release there from the pituitary, or whether GH exerts CNS effects by secondary mediators, particularly insulin-like growth factor (IGF)-1. GH release from the pituitary is controlled not only by hypothalamic factors, but also by gh...
متن کاملP 61: MicroRNA as a Therapeutic Tool to Prevent Blood Brain Barrier Dysfunction in Neuroinflammation
Endothelial cells present in brain are unique and differ from other peripheral tissues in a number of ways, which ensures specific brain endothelial barrier properties. Endothelial dysfunction is the earliest event in the initiation of vascular damage caused by inflammation. Various microRNAs (miRNA) have been discovered in different cellular components of the blood bran barrier (BBB). miRNAs a...
متن کاملP 136: The Role of Blood Brain Barrier in Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disorder, in which neurons become demyelinated. To date, its etiology has remained unknown. Nevertheless, certain features are inspected to provoke MS. For instance, improper function of immune cells is widely believed to be the basis of such disorder. In this concept, MS is stated as an autoimmune disease, which was asserted by major of studies, as CD...
متن کاملIn Silico Design and Verification of LAMP-BDNF Chimeric Protein for Presentation of BDNF on the Surface of Exosomes for Drug Delivery Through Blood-Brain Barrier
Background and purpose: The mature form of brain-derived neurotrophic factor (BDNF) binds to BDNF/NT-3 growth factors receptor (Trk-B). This binding leads to activation of Ras–MAPK pathway which is integrated with cell growth and proliferation. The BDNF deficiency is correlated with various diseases and affects aging and miscellaneous. In the present study we aimed to design a chimeric LAMP-BDN...
متن کاملFormulation of temozolomide by folic acid-conjugated tri-block copolymer nanoparticles for targeted drug delivery
Introduction: Glioblastoma multiforme (GBM) is the most frequent primary malignant tumor of the brain. But, the treatment of GBM is one of the most problems in cancer therapy because of poor drug penetration across the blood-brain barrier (BBB). Targeting drug delivery system and conjugating targeting moieties was recognized to overcome the poor penetration of chemotherapy drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of pharmacology and experimental therapeutics
دوره 302 2 شماره
صفحات -
تاریخ انتشار 2002